Louis Lavigne

Louis J. Lavigne, Jr. is a prominent figure in corporate finance and management, currently serving as the Chairperson of the Board of Directors at Alector, Inc., a biotechnology company focused on developing therapies for neurodegenerative diseases. He has been on Alector's board since 2018 and became chairperson in June 2023. Lavigne is also a member of the Audit and Compensation Committees at Alector.34

Professional Background

Lavigne has an extensive career in the biotech industry, having retired as Executive Vice President and Chief Financial Officer of Genentech, Inc. in 2005 after a 23-year tenure. During his time at Genentech, he was responsible for various critical departments including financial operations and corporate relations, and he was recognized as the Best CFO in Biotech by Institutional Investor in 2005.135

In addition to his role at Alector, Lavigne is the Managing Partner of Laman Partners, LLC, a management consulting firm, and has been the Managing Director of Lavrite, LLC since 2005. His consulting work focuses on corporate finance, accounting, and growth strategy.13

Board Memberships

Lavigne has served on multiple boards across various sectors. His past and present board memberships include:

• Zynga Inc. (2015 - May 2022)
• Accuray Inc. (Chairman from 2009 to June 2021)
• DocuSign Inc. (2013 - May 2020)
• NovoCure Limited (2013 - October 2018)
• Rodan + Fields LLC (2015 - July 2021)

He has also held leadership roles on audit and compensation committees for several of these organizations.235

Education

Lavigne holds a Bachelor of Science in Finance from Babson College and an MBA from Temple University, which underpin his expertise in finance and management.13

Summary

Louis J. Lavigne, Jr. is recognized for his significant contributions to corporate governance and finance within the biotech sector, bringing decades of experience to his current roles as chairperson and managing partner while actively participating in various board capacities across multiple companies.